<p>在过去三个月中，19 位分析师对 Inspire Medical Systems（纽约证券交易所：INSP）发布了评级，呈现出从看涨到看跌的广泛观点。</p>
<p>总结他们最近的评估，下面的表格展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师为 Inspire Medical Systems 设定了 12 个月的价格目标，显示出平均目标为 124.11 美元，最高预估为 180.00 美元，最低预估为 70.00 美元。目前的平均价格目标较之前的 127.35 美元下降了 2.54%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770901236_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770901236_0.png"/></p>
<h2>解读分析师评级：更深入的观察</h2>
<p>通过对最近分析师行动的全面分析，描绘出 Inspire Medical Systems 在金融专家中的认知。下面的总结概述了关键分析师、他们最近的评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>下调</td>
<td>超配</td>
<td>$85.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>下调</td>
<td>持有</td>
<td>$70.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>下调</td>
<td>超过市场</td>
<td>$85.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>下调</td>
<td>等权重</td>
<td>$70.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>下调</td>
<td>中性</td>
<td>$74.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下调</td>
<td>行业表现</td>
<td>$90.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>下调</td>
<td>超配</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>下调</td>
<td>买入</td>
<td>$120.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>上调</td>
<td>中性</td>
<td>$91.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超过市场</td>
<td>$175.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>上调</td>
<td>超过市场</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>上调</td>
<td>中性</td>
<td>$118.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>超配</td>
<td>$165.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>宣布</td>
<td>超过市场</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>上调</td>
<td>超过市场</td>
<td>$180.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>等权重</td>
<td>$130.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$165.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>宣布</td>
<td>超过市场</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>上调</td>
<td>买入</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>关键洞察：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师对市场条件和公司表现的变化作出反应，频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，反映了他们对 Inspire Medical Systems 最近发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 分析师从定性角度全面评估股票，从 “超过市场” 到 “低于市场”。这些评级传达了对 Inspire Medical Systems 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师提供对 Inspire Medical Systems 股票未来价值的估计，揭示了分析师预期随时间变化的趋势。</li>
</ul>
<p>理解这些分析师评估与关键财务指标相结合，可以为 Inspire Medical Systems 的市场地位提供有价值的洞察。保持信息灵通，利用我们的评级表做出深思熟虑的决策。</p>
<p>随时了解 Inspire Medical Systems 的分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>发现 Inspire Medical Systems：更深入的观察</h2>
<p>Inspire Medical Systems Inc 是一家医疗技术公司，专注于开发和商业化针对阻塞性睡眠呼吸暂停（OSA）患者的微创解决方案。它提供 Inspire 系统，这是一种神经刺激技术，为中度至重度阻塞性睡眠呼吸暂停提供安全有效的治疗。该公司在美国和欧洲运营，其中大部分收入来自美国。</p>
<h3>解开 Inspire Medical Systems 的财务故事</h3>
<p><strong>市值：</strong> 由于市值受限，该公司在行业平均水平以下。这反映出相对于同行的较小规模。</p>
<p><strong>收入增长：</strong> Inspire Medical Systems 在第三季度表现出积极的结果。截至 2025 年 9 月 30 日，该公司实现了约 <strong>10.49%</strong> 的稳健收入增长率。这表明公司的顶线收益显著增加。与医疗保健行业的其他公司相比，该公司的增长率低于同行的平均水平，面临挑战。</p>
<p><strong>净利润率：</strong> Inspire Medical Systems 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率达到 <strong>4.42%</strong>，展现出强劲的盈利能力和有效的成本管理。</p>
<p><strong>股本回报率（ROE）：</strong> Inspire Medical Systems 的 ROE 表现突出，超过行业平均水平。该公司的 ROE 达到 <strong>1.48%</strong>，展示了对股本资本的有效利用和强劲的财务表现。</p>
<p><strong>资产回报率 (ROA)：</strong> 公司的资产回报率表现突出，超过行业平均水平。公司以 <strong>1.23%</strong> 的令人印象深刻的资产回报率展示了资产的有效利用。</p>
<p><strong>债务管理：</strong> Inspire Medical Systems 的债务与股本比率低于行业平均水平，为 <strong>0.05</strong>，反映出对债务融资的依赖较低以及更为保守的财务策略。</p>
<h2>分析师评级的核心：每位投资者应知晓的事项</h2>
<p>Benzinga 跟踪 150 家分析师公司并报告他们的股票预期。分析师通常通过预测公司未来的盈利能力，通常是接下来的五年，以及该公司收入来源的风险或可预测性来得出结论。</p>
<p>分析师参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布他们对股票的评级。分析师通常每季度对每只股票进行一次评级，或在公司有重大更新时进行评级。</p>
<p>一些分析师还会提供增长预估、收益和收入等指标的预测，以进一步指导股票投资。使用分析师评级的投资者应注意，这些专业建议来自人类，可能会存在错误。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

启迪医疗

纽交所高增长板生物技术指数 ETF - First Trust

<p>启迪医疗系统（NYSE:INSP）在过去三个月内收到了 19 位分析师的评级，显示出看涨和看跌情绪的混合。12 个月的平均目标价为 124.11 美元，较之前的 127.35 美元有所下降。近期的行动包括几位分析师下调了他们的评级和目标价，而少数分析师则上调了这些指标。该公司专注于治疗阻塞性睡眠呼吸暂停的微创解决方案，报告的收入增长率为 10.49%，并保持强劲的盈利能力，净利润率为 4.42%。其债务与股本比率低至 0.05，表明其财务管理较为保守</p>

<p>In the preceding three months, 19 analysts have released ratings for Inspire Medical Systems (NYSE: INSP), presenting a wide array of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在过去三个月中，19 位分析师对 Inspire Medical Systems（纽约证券交易所：INSP）发布了评级，呈现出从看涨到看跌的广泛观点。</p>
</div><p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<div class="lb-trans"><p>总结他们最近的评估，下面的表格展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for Inspire Medical Systems, revealing an average target of $124.11, a high estimate of $180.00, and a low estimate of $70.00. A 2.54% drop is evident in the current average compared to the previous average price target of $127.35.</p>
<div class="lb-trans"><p>分析师为 Inspire Medical Systems 设定了 12 个月的价格目标，显示出平均目标为 124.11 美元，最高预估为 180.00 美元，最低预估为 70.00 美元。目前的平均价格目标较之前的 127.35 美元下降了 2.54%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770901236_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770901236_0.png"/></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<div class="lb-trans"><h2>解读分析师评级：更深入的观察</h2>
</div><p>A clear picture of Inspire Medical Systems's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过对最近分析师行动的全面分析，描绘出 Inspire Medical Systems 在金融专家中的认知。下面的总结概述了关键分析师、他们最近的评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$91.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$118.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>下调</td>
<td>超配</td>
<td>$85.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>下调</td>
<td>持有</td>
<td>$70.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>下调</td>
<td>超过市场</td>
<td>$85.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>下调</td>
<td>等权重</td>
<td>$70.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>下调</td>
<td>中性</td>
<td>$74.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下调</td>
<td>行业表现</td>
<td>$90.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>下调</td>
<td>超配</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>下调</td>
<td>买入</td>
<td>$120.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>上调</td>
<td>中性</td>
<td>$91.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超过市场</td>
<td>$175.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>上调</td>
<td>超过市场</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>上调</td>
<td>中性</td>
<td>$118.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>超配</td>
<td>$165.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>宣布</td>
<td>超过市场</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>上调</td>
<td>超过市场</td>
<td>$180.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>等权重</td>
<td>$130.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$165.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>宣布</td>
<td>超过市场</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>上调</td>
<td>买入</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键洞察：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Inspire Medical Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Inspire Medical Systems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Inspire Medical Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师对市场条件和公司表现的变化作出反应，频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，反映了他们对 Inspire Medical Systems 最近发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 分析师从定性角度全面评估股票，从 “超过市场” 到 “低于市场”。这些评级传达了对 Inspire Medical Systems 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师提供对 Inspire Medical Systems 股票未来价值的估计，揭示了分析师预期随时间变化的趋势。</li>
</ul>
</div><p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Inspire Medical Systems's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<div class="lb-trans"><p>理解这些分析师评估与关键财务指标相结合，可以为 Inspire Medical Systems 的市场地位提供有价值的洞察。保持信息灵通，利用我们的评级表做出深思熟虑的决策。</p>
</div><p>Stay up to date on Inspire Medical Systems analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Inspire Medical Systems 的分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>Discovering Inspire Medical Systems: A Closer Look</h2>
<div class="lb-trans"><h2>发现 Inspire Medical Systems：更深入的观察</h2>
</div><p>Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.</p>
<div class="lb-trans"><p>Inspire Medical Systems Inc 是一家医疗技术公司，专注于开发和商业化针对阻塞性睡眠呼吸暂停（OSA）患者的微创解决方案。它提供 Inspire 系统，这是一种神经刺激技术，为中度至重度阻塞性睡眠呼吸暂停提供安全有效的治疗。该公司在美国和欧洲运营，其中大部分收入来自美国。</p>
</div><h3>Unraveling the Financial Story of Inspire Medical Systems</h3>
<div class="lb-trans"><h3>解开 Inspire Medical Systems 的财务故事</h3>
</div><p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<div class="lb-trans"><p><strong>市值：</strong> 由于市值受限，该公司在行业平均水平以下。这反映出相对于同行的较小规模。</p>
</div><p><strong>Revenue Growth:</strong> Inspire Medical Systems displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately <strong>10.49%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Inspire Medical Systems 在第三季度表现出积极的结果。截至 2025 年 9 月 30 日，该公司实现了约 <strong>10.49%</strong> 的稳健收入增长率。这表明公司的顶线收益显著增加。与医疗保健行业的其他公司相比，该公司的增长率低于同行的平均水平，面临挑战。</p>
</div><p><strong>Net Margin:</strong> Inspire Medical Systems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>4.42%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Inspire Medical Systems 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率达到 <strong>4.42%</strong>，展现出强劲的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> Inspire Medical Systems's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.48%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Inspire Medical Systems 的 ROE 表现突出，超过行业平均水平。该公司的 ROE 达到 <strong>1.48%</strong>，展示了对股本资本的有效利用和强劲的财务表现。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.23%,</strong> the company showcases effective utilization of assets.</p>
<div class="lb-trans"><p><strong>资产回报率 (ROA)：</strong> 公司的资产回报率表现突出，超过行业平均水平。公司以 <strong>1.23%</strong> 的令人印象深刻的资产回报率展示了资产的有效利用。</p>
</div><p><strong>Debt Management:</strong> Inspire Medical Systems's debt-to-equity ratio is below the industry average at <strong>0.05</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Inspire Medical Systems 的债务与股本比率低于行业平均水平，为 <strong>0.05</strong>，反映出对债务融资的依赖较低以及更为保守的财务策略。</p>
</div><h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<div class="lb-trans"><h2>分析师评级的核心：每位投资者应知晓的事项</h2>
</div><p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<div class="lb-trans"><p>Benzinga 跟踪 150 家分析师公司并报告他们的股票预期。分析师通常通过预测公司未来的盈利能力，通常是接下来的五年，以及该公司收入来源的风险或可预测性来得出结论。</p>
</div><p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<div class="lb-trans"><p>分析师参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布他们对股票的评级。分析师通常每季度对每只股票进行一次评级，或在公司有重大更新时进行评级。</p>
</div><p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<div class="lb-trans"><p>一些分析师还会提供增长预估、收益和收入等指标的预测，以进一步指导股票投资。使用分析师评级的投资者应注意，这些专业建议来自人类，可能会存在错误。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

What 19 Analyst Ratings Have To Say About Inspire Medical Systems

benzinga_article

19 位分析师对启迪医疗系统的评级意见是什么